Thomas M. Hart, Yingjun Cui, Sam R. Telford, Alejandro Marín-López, Keith Calloway, Yile Dai, Jaqueline Matias, Kathleen DePonte, Jillian Jaycox, Melody DeBlasio, Dieuwertje Hoornstra, Alexia A. Belperron, Balasubramanian Cibichakravarthy, Emily E. Johnson, Mohamad-Gabriel Alameh, Garima Dwivedi, Joppe W. R. Hovius, Linda K. Bockenstedt, Drew Weissman, Aaron M. Ring, Erol Fikrig
{"title":"Tick feeding or vaccination with tick antigens elicits immunity to the Ixodes scapularis exoproteome in guinea pigs and humans","authors":"Thomas M. Hart, Yingjun Cui, Sam R. Telford, Alejandro Marín-López, Keith Calloway, Yile Dai, Jaqueline Matias, Kathleen DePonte, Jillian Jaycox, Melody DeBlasio, Dieuwertje Hoornstra, Alexia A. Belperron, Balasubramanian Cibichakravarthy, Emily E. Johnson, Mohamad-Gabriel Alameh, Garima Dwivedi, Joppe W. R. Hovius, Linda K. Bockenstedt, Drew Weissman, Aaron M. Ring, Erol Fikrig","doi":"10.1126/scitranslmed.ads9207","DOIUrl":null,"url":null,"abstract":"<div ><i>Ixodes scapularis</i> is a primary vector of tick-borne pathogens in North America. Repeated exposure to these ticks can induce a humoral response to tick antigens and acquired tick resistance. However, identifying antigens contributing to this resistance is challenging because of the vast number of <i>I. scapularis</i> proteins secreted during feeding. To address this, we developed <i>I. scapularis</i> rapid extracellular antigen monitoring (<i>Isc</i>REAM), a technique to detect antibody responses to more than 3000 tick antigens. We validated <i>Isc</i>REAM with immunoglobulin G (IgG) from guinea pigs vaccinated with tick antigens, including a cement antigen cocktail that induced tick resistance. Furthermore, we explored the natural response to tick bites by profiling antigens recognized by IgG isolated from a tick-resistant individual, as well as from others with Lyme disease and tick-bitten guinea pigs and mice, to identify 199 recognized antigens. We observed that several antigens contained histamine-binding domains. This work enhances our understanding of the host immune response to <i>I. scapularis</i> and defines immunogen candidates for future antitick vaccines.</div>","PeriodicalId":21580,"journal":{"name":"Science Translational Medicine","volume":"17 791","pages":""},"PeriodicalIF":14.6000,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Science Translational Medicine","FirstCategoryId":"3","ListUrlMain":"https://www.science.org/doi/10.1126/scitranslmed.ads9207","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Ixodes scapularis is a primary vector of tick-borne pathogens in North America. Repeated exposure to these ticks can induce a humoral response to tick antigens and acquired tick resistance. However, identifying antigens contributing to this resistance is challenging because of the vast number of I. scapularis proteins secreted during feeding. To address this, we developed I. scapularis rapid extracellular antigen monitoring (IscREAM), a technique to detect antibody responses to more than 3000 tick antigens. We validated IscREAM with immunoglobulin G (IgG) from guinea pigs vaccinated with tick antigens, including a cement antigen cocktail that induced tick resistance. Furthermore, we explored the natural response to tick bites by profiling antigens recognized by IgG isolated from a tick-resistant individual, as well as from others with Lyme disease and tick-bitten guinea pigs and mice, to identify 199 recognized antigens. We observed that several antigens contained histamine-binding domains. This work enhances our understanding of the host immune response to I. scapularis and defines immunogen candidates for future antitick vaccines.
期刊介绍:
Science Translational Medicine is an online journal that focuses on publishing research at the intersection of science, engineering, and medicine. The goal of the journal is to promote human health by providing a platform for researchers from various disciplines to communicate their latest advancements in biomedical, translational, and clinical research.
The journal aims to address the slow translation of scientific knowledge into effective treatments and health measures. It publishes articles that fill the knowledge gaps between preclinical research and medical applications, with a focus on accelerating the translation of knowledge into new ways of preventing, diagnosing, and treating human diseases.
The scope of Science Translational Medicine includes various areas such as cardiovascular disease, immunology/vaccines, metabolism/diabetes/obesity, neuroscience/neurology/psychiatry, cancer, infectious diseases, policy, behavior, bioengineering, chemical genomics/drug discovery, imaging, applied physical sciences, medical nanotechnology, drug delivery, biomarkers, gene therapy/regenerative medicine, toxicology and pharmacokinetics, data mining, cell culture, animal and human studies, medical informatics, and other interdisciplinary approaches to medicine.
The target audience of the journal includes researchers and management in academia, government, and the biotechnology and pharmaceutical industries. It is also relevant to physician scientists, regulators, policy makers, investors, business developers, and funding agencies.